LEXINGTON, Mass.--(BUSINESS WIRE)--May 14, 2009--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), today announced that
preliminary results from the Phase 3 trial (SYMMETRYSM) of
elesclomol in metastatic melanoma will be the subject of an oral
presentation in the Melanoma session at the 2009 Annual Meeting of the
American Society of Clinical Oncology (ASCO) in Orlando, Florida.
Dr. Steven O'Day, Chief of Research and Director of the Melanoma Program
at The Angeles Clinic and Research Institute and the North America
Principal Investigator on the SYMMETRY trial will present preliminary
data from the trial comparing elesclomol in combination with paclitaxel
to paclitaxel alone in chemo-naïve patients with stage IV metastatic
melanoma.
The oral presentation is scheduled for Saturday, May 30 from 3:30 - 3:45
p.m. ET in West Hall F3 at the Orlando Convention Center.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to
extend and enhance the lives of patients with severe medical conditions,
including cancer and chronic inflammatory diseases. Synta has a unique
chemical compound library, an integrated discovery engine, and a diverse
pipeline of clinical- and preclinical-stage drug candidates with
distinct mechanisms of action and novel chemical structures. All Synta
drug candidates were invented by Synta scientists using our compound
library and discovery capabilities. For more information, please visit www.syntapharma.com.
Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125
